

## Review Form 1.6

Journal Name:	<a href="#">Journal of Advances in Medicine and Medical Research</a>
Manuscript Number:	Ms_JAMMR_86125
Title of the Manuscript:	COVID-19 Vaccination: Early Estimates of a Relative Post Interventional Case Fatality Risk
Type of the Article	Original Research Article

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljammr.com/index.php/JAMMR/editorial-policy> )

**Review Form 1.6**

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p><b>Compulsory</b> REVISION comments</p>	<p>It is an honour for me to review the manuscript number “Ms_JAMMR_86125” titled “COVID-19 Vaccination: Early Estimates of a Relative Post Interventional Case Fatality Risk” for the “Journal of Advances in Medicine and Medical Research’.</p> <p>The paper is really good and very well written. However, there are suggestions that I must make concerning this work in order to improve the overall level of this manuscript to merit publication in this journal.</p> <ol style="list-style-type: none"> <li>1) Given the presence of a few English mistakes (grammatical, typos and run-on sentence) I will advice the authors to check their manuscript another time and make a revision by native English or even a specialist.</li> <li>2) Before starting your introduction by talking directly about COVID-19 vaccines, you should start by short paragraph (or at least 2-3 sentences) about the SARS-Cov-2, the emergence of the epidemic, the number of cases, the actual situation, at what moment was it declared a pandemic...etc.</li> <li>3) Concerning CFR, you should specify that in the beginning of the epidemic, in the first months, the higher CFR was in Algeria with about 15% , please cite this reference: <ul style="list-style-type: none"> <li>• Aouissi, H. A., &amp; Belhaouchet, I. (2021). What about rheumatic diseases and COVID-19?. <i>New microbes and new infections</i>, 41, 100846. <a href="https://doi.org/10.1016/j.nmni.2021.100846">https://doi.org/10.1016/j.nmni.2021.100846</a></li> <li>• Lounis M. (2021). COVID-19: Why Algeria's Case Fatality Rate Seems to be Among the Highest in the World?. <i>The Eurasian journal of medicine</i>, 53(2), 160–161. <a href="https://doi.org/10.5152/eurasianjmed.2021.20192">https://doi.org/10.5152/eurasianjmed.2021.20192</a></li> </ul> </li> <li>4) Regarding the references you cited, there is a lack of references in your paper, please add these references following my suggestions between brackets or in another location: <ul style="list-style-type: none"> <li>• Aouissi H. A. (2021). Algeria's preparedness for Omicron variant and for the fourth wave of COVID-19. <i>Global health &amp; medicine</i>, 3(6), 413–414. <a href="https://doi.org/10.35772/ghm.2021.01117">https://doi.org/10.35772/ghm.2021.01117</a> (concerning omicron)</li> <li>• Leveau, C. M., Aouissi, H. A., &amp; Kebaili, F. K. (2022). Spatial diffusion of COVID-19 in Algeria during the third wave. <i>GeoJournal</i>, 1–6. Advance online publication. <a href="https://doi.org/10.1007/s10708-022-10608-5">https://doi.org/10.1007/s10708-022-10608-5</a> (Concerning the other variants or the pre-vaccination period)</li> <li>• Al-Ali, D., Elshafeey, A., Mushannen, M., Kawas, H., Shafiq, A., Mhaimeed, N., Mhaimeed, O., Mhaimeed, N., Zeghlache, R., Salameh, M., Paul, P., Homssi, M., Mohammed, I., Narangoli, A., Yagan, L., Khanjar, B., Laws, S., Elshazly, M. B., &amp; Zakaria, D. (2022). Cardiovascular and haematological events post COVID-19 vaccination: A systematic review. <i>Journal of cellular and molecular medicine</i>, 26(3), 636–653. <a href="https://doi.org/10.1111/jcmm.17137">https://doi.org/10.1111/jcmm.17137</a> (concerning post-vaccination).</li> <li>• Aouissi, H. A., Ababsa, M., Leveau, C., Petrisor, A. I., Slomka, A., Yasuhara, J., Epelboin, L. &amp; Ohmagari, N. (2022). Beyond vaccination: A Cross-Sectional Study of the importance of Behavioral and Native Factors on COVID-19 Infection and Severity. medRxiv.</li> <li>• Joshi, G., Borah, P., Thakur, S., Sharma, P., Mayank, &amp; Poduri, R. (2021). Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. <i>Human vaccines &amp; immunotherapeutics</i>, 17(12), 4714–4740.</li> </ul> </li> </ol>	

Review Form 1.6

	<a href="https://doi.org/10.1080/21645515.2021.1995283">https://doi.org/10.1080/21645515.2021.1995283</a>	
	5) Your conclusion is a little weak, please try to improve it.	
<b>Minor</b> REVISION comments	1) Please do not write in <b>bold</b> 2) Please try to avoid to repeat COVID-19 every line, specifically in the methods section	
<b>Optional/General</b> comments	1) Please try to write with the same policy in the entire manuscript.	

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<u>(If yes, Kindly please write down the ethical issues here in details)</u>	

Reviewer Details:

Name:	Hani Amir Aouissi
Department, University & Country	Scientific and Technical Research Center on Arid Regions (CRSTRA), Algeria